Page 8 - க்ளேண்மர்க் மருந்துகள் வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Glenmark Pharmaceuticals receives ANDA approval for Topiramate Extended-Release Capsules Posted On: 2021-02-02 20:38:31 (Time Zone: Arizona, USA) Glenmark Pharmaceuticals Limited (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg, the generic version of Qudexy® XR Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg, of Upsher-Smith Laboratories, LLC. According to IQVIA™ sales data for the 12 month period ending December 2020, the Qudexy® XR Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg market achieved annual sales of approximately $120.8 million . Glenmark s current portfolio consists of 169 products authorized for distribution in the U.S. marketplace and 43 ANDA s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accel

United statesUpsher smith laboratoriesGlenmark pharmaceuticals limitedGlenmark pharmaceuticalsUnited states food drug administrationTopiramate extended releaseTime zonePharmaceuticals limitedUnited states foodDrug administrationTopiramate extended release capsulesஒன்றுபட்டது மாநிலங்களில்க்ளேண்மர்க் மருந்துகள் வரையறுக்கப்பட்டவைக்ளேண்மர்க் மருந்துகள்நேரம் ஸோந்மருந்துகள் வரையறுக்கப்பட்டவை